Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.
Public ClinicalTrials.gov record NCT00471081. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Study to Assess Immunogenicity, Reactogenicity and Safety of Primary Vaccination With GSK Biologicals' MenACWY Vaccine (GSK134612) Given as 1 or 2 Doses to Healthy Toddlers 9-12 Months of Age
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to characterize the safety and immunogenicity of 1 dose of GSK134612 vaccine at 12 months of age and of GSK134612 vaccine administered as 2 doses at 9 and 12 months of age.
Study identification
- NCT ID
- NCT00471081
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 385 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 9 Months to 9 Months
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 4, 2007
- Primary completion
- Oct 22, 2008
- Completion
- Nov 25, 2008
- Last update posted
- Jun 24, 2019
2007 – 2008
United States locations
- U.S. sites
- 19
- U.S. states
- 8
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35205 | — |
| GSK Investigational Site | Benton | Arkansas | 72015 | — |
| GSK Investigational Site | Little Rock | Arkansas | 72205 | — |
| GSK Investigational Site | Antioch | California | 94509 | — |
| GSK Investigational Site | Fremont | California | 94538 | — |
| GSK Investigational Site | Hayward | California | 94545 | — |
| GSK Investigational Site | Madera | California | 93637 | — |
| GSK Investigational Site | Santa Rosa | California | 95403 | — |
| GSK Investigational Site | Vacaville | California | 95688 | — |
| GSK Investigational Site | Lakewood | Colorado | 80226 | — |
| GSK Investigational Site | Littleton | Colorado | 80122 | — |
| GSK Investigational Site | Littleton | Colorado | 80234 | — |
| GSK Investigational Site | Westminster | Colorado | 80234 | — |
| GSK Investigational Site | Wheat Ridge | Colorado | 80033 | — |
| GSK Investigational Site | Birmingham | Georgia | 35244 | — |
| GSK Investigational Site | Canton | Ohio | 44718 | — |
| GSK Investigational Site | Erie | Pennsylvania | 16501 | — |
| GSK Investigational Site | Greenville | Pennsylvania | 16125 | — |
| GSK Investigational Site | Amarillo | Texas | 79124 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00471081, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 24, 2019 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00471081 live on ClinicalTrials.gov.